In 2013, Yamawaki et al found that DEX enhanced the extracellular secretion of cystatin C in esophageal cancer cells [26], suggesting that DEX treatment may be one of the reasons for the increased serum cystatin C concentration seen in patients with cancer during chemotherapy [11,27]. Here, CST3 is linked to esophageal cancer.